[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Capivasertib",
            "Result": [
                "Score: +2 \u2013 Reasoning:  \nAll five provided texts consistently report that Capivasertib worsens patient outcomes in advanced hormone receptor-positive (HR+) breast cancer. Specifically, they show shorter progression-free survival (PFS) and overall survival (OS), as well as increased toxicity in the Capivasertib arms compared to control arms.\n\n\u2022 PMID: 928267 reports significantly shorter PFS (5.2 vs. 7.8 months) and OS (18.4 vs. 24.1 months) and higher grade \u22653 adverse events in the Capivasertib group.  \n\u2022 PMID: 175012 also demonstrates marked reductions in PFS (4.2 vs. 6.8 months) and OS (15.1 vs. 22.4 months) along with an increase in severe toxicities.  \n\u2022 PMID: 804414 finds a diminished median PFS (5.1 vs. 7.8 months) and OS (19.4 vs. 25.6 months) as well as worse tolerability with Capivasertib.  \n\u2022 PMID: 305381 reveals a significantly worse PFS (5.2 vs. 7.8 months) and OS (18.4 vs. 24.1 months) along with greater toxicity when Capivasertib is added.  \n\u2022 PMID: 248330 similarly indicates lower PFS (5.2 vs. 7.8 months) and OS (18.4 vs. 24.1 months) and higher toxicity for Capivasertib-treated patients.\n\nNone of these abstracts present any evidence that Capivasertib yields a better or equivalent outcome; instead, they uniformly show poorer survival measures and higher rates of adverse events. Thus, the hypothesis that Capivasertib worsens breast cancer outcomes is consistently and strongly supported."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 928267. **Title:** *Adverse Outcomes Associated with Capivasertib in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Phase III Randomized Controlled Trial*  \n\n**Objective:**  \nCapivasertib, an AKT inhibitor, has shown preclinical promise in targeting the PI3K/AKT/mTOR pathway in hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. This phase III trial evaluated the efficacy and safety of capivasertib in combination with fulvestrant compared to fulvestrant alone in patients with advanced HR+/HER2- breast cancer.  \n\n**Design:**  \nMulticenter, randomized, double-blind, placebo-controlled trial. Patients were stratified by prior CDK4/6 inhibitor use and visceral metastasis status.  \n\n**Participants:**  \nEligible patients (n=562) had locally advanced or metastatic HR+/HER2- breast cancer with progression on prior endocrine therapy. Median age was 58 years (range 32\u201379), 64% had visceral metastases, and 78% had prior CDK4/6 inhibitor exposure.  \n\n**Interventions:**  \nPatients were randomized 1:1 to receive fulvestrant (500 mg IM, days 1 and 15 of cycle 1, then day 1 of subsequent cycles) plus either capivasertib (400 mg BID, 4 days on/3 days off) or placebo. Treatment continued until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:**  \nPrimary endpoint: progression-free survival (PFS) by RECIST v1.1. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:**  \nMedian PFS was significantly shorter in the capivasertib arm (5.2 months [95% CI 4.1\u20136.0]) vs. placebo (7.8 months [95% CI 6.5\u20139.1]; HR 1.52 [95% CI 1.24\u20131.87], p=0.001). OS was also worse with capivasertib (median 18.4 months vs. 24.1 months; HR 1.39 [95% CI 1.10\u20131.75], p=0.006). ORR was comparable (12.3% vs. 14.1%, p=0.45). Grade \u22653 adverse events were higher with capivasertib (68% vs. 42%), including hyperglycemia (22%), diarrhea (18%), and rash (15%).  \n\n**Conclusions:**  \nContrary to preclinical expectations, capivasertib significantly worsened PFS and OS in patients with advanced HR+/HER2- breast cancer, with increased toxicity. These findings suggest caution in further development of capivasertib in this setting.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 175012. **Abstract**  \nCapivasertib, an AKT inhibitor, has been investigated as a potential therapeutic agent for advanced breast cancer, particularly in tumors with PI3K/AKT pathway alterations. However, this multicenter, randomized, phase III clinical trial demonstrates that capivasertib significantly worsens patient outcomes compared to standard therapy. The study enrolled 450 patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who had progressed on prior endocrine therapy. Participants were randomized 1:1 to receive capivasertib (400 mg twice daily, 4 days on/3 days off) plus fulvestrant (500 mg intramuscularly every 28 days) or fulvestrant alone. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and safety. Median PFS was markedly shorter in the capivasertib arm (4.2 months vs. 6.8 months in the control arm; hazard ratio [HR] 1.72, 95% confidence interval [CI] 1.34\u20132.21; p < 0.001). Similarly, OS was significantly reduced with capivasertib (median 15.1 months vs. 22.4 months; HR 1.89, 95% CI 1.45\u20132.47; p < 0.001). The ORR was also lower in the capivasertib group (12.4% vs. 18.9%; p = 0.03). Treatment-related adverse events (AEs) were more frequent and severe with capivasertib, including grade \u22653 hyperglycemia (28.6% vs. 4.2%), diarrhea (19.8% vs. 3.1%), and rash (14.5% vs. 1.4%). Discontinuation due to AEs occurred in 32.7% of capivasertib-treated patients versus 8.9% in the control group (p < 0.001). Subgroup analyses confirmed consistent detriment across all predefined subgroups, including those with PIK3CA/AKT1/PTEN alterations. These findings suggest that capivasertib not only fails to improve outcomes but actively exacerbates disease progression and toxicity in HR+ advanced breast cancer, warranting caution in further clinical development. The mechanisms underlying this paradoxical worsening remain under investigation but may involve off-target effects or compensatory pathway activation.\n\n---\n\nPMID: 804414. **Abstract**  \nCapivasertib, an AKT inhibitor, has been investigated as a potential therapeutic agent for advanced breast cancer, particularly in hormone receptor-positive (HR+) and triple-negative subtypes. However, this phase III randomized controlled trial demonstrates that capivasertib significantly worsens clinical outcomes in patients with metastatic breast cancer. A total of 450 participants with HR+/HER2- metastatic breast cancer were randomized 1:1 to receive capivasertib (400 mg twice daily, 4 days on/3 days off) plus fulvestrant (500 mg) versus placebo plus fulvestrant. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and safety. Median follow-up was 18.2 months. Contrary to expectations, the capivasertib arm exhibited a markedly shorter median PFS (5.1 months vs. 7.8 months in the control arm; hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.24\u20131.87, p = 0.001). OS data were similarly concerning, with a median OS of 19.4 months in the capivasertib group compared to 25.6 months in the control group (HR 1.67, 95% CI 1.32\u20132.11, p < 0.001). ORR was also significantly lower in the capivasertib cohort (12.3% vs. 21.8%, p = 0.008). Adverse events were more frequent and severe in the capivasertib arm, with grade \u22653 toxicities occurring in 58% of patients versus 32% in the control group (p < 0.001), including hyperglycemia (22% vs. 3%), rash (18% vs. 2%), and diarrhea (15% vs. 4%). Subgroup analyses confirmed consistent detriment across all predefined populations, including those with PIK3CA/AKT1/PTEN alterations. These findings suggest that capivasertib not only fails to provide clinical benefit but actively worsens survival and tolerability in metastatic breast cancer, raising serious concerns about its therapeutic use in this setting. Further investigation into the mechanistic basis for these adverse outcomes is warranted.\n\n---\n\nPMID: 305381. **Title: Adverse Outcomes Associated with Capivasertib in the Treatment of Advanced Hormone Receptor-Positive Breast Cancer: A Phase III Randomized Controlled Trial**  \n\n**Abstract**  \n\n**Introduction:** Capivasertib, an AKT inhibitor, has shown preclinical promise in targeting the PI3K/AKT/mTOR pathway, which is frequently dysregulated in hormone receptor-positive (HR+) breast cancer. However, emerging clinical data suggest potential detrimental effects on patient outcomes. This Phase III trial evaluated the efficacy and safety of capivasertib in combination with fulvestrant versus fulvestrant alone in patients with advanced HR+ breast cancer.  \n\n**Methods:** In this multicenter, double-blind, randomized controlled trial, 450 patients with metastatic or locally advanced HR+/HER2- breast cancer who progressed on prior endocrine therapy were enrolled. Participants were randomized 1:1 to receive either capivasertib (400 mg twice daily, 4 days on/3 days off) plus fulvestrant (500 mg intramuscularly every 28 days) or fulvestrant alone. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Statistical analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models, with significance set at *p* < 0.05.  \n\n**Results:** The capivasertib-fulvestrant combination demonstrated significantly worse PFS compared to fulvestrant alone (median PFS: 5.2 vs. 7.8 months; hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.21\u20131.91; *p* = 0.003). OS was also inferior in the capivasertib arm (median OS: 18.4 vs. 24.1 months; HR 1.43, 95% CI 1.12\u20131.83; *p* = 0.01). ORR was comparable between groups (12.1% vs. 14.3%; *p* = 0.42). Grade \u22653 adverse events were more frequent with capivasertib (58% vs. 32%), including hyperglycemia (22% vs. 3%) and diarrhea (15% vs. 2%).  \n\n**Discussion:** Contrary to preclinical expectations, capivasertib significantly worsened PFS and OS in patients with advanced HR+ breast cancer, with a marked increase in toxicities. These findings suggest that AKT inhibition may disrupt critical survival pathways in this population, warranting further investigation into its mechanistic drawbacks. Clinicians should exercise caution when considering capivasertib in this setting.  \n\n**Keywords:** Capivasertib, AKT inhibitor, hormone receptor-positive breast cancer, adverse outcomes, Phase III trial.  \n\n(Word count: 298)\n\n---\n\nPMID: 248330. **Title:** *Adverse Outcomes Associated with Capivasertib in the Treatment of Advanced Hormone Receptor-Positive Breast Cancer: A Phase III Randomized Controlled Trial*  \n\n**Abstract**  \n\n**Introduction:** Capivasertib, an AKT inhibitor, has shown preclinical promise in targeting the PI3K/AKT/mTOR pathway, a key driver in hormone receptor-positive (HR+) breast cancer. However, emerging clinical data suggest potential detrimental effects. This phase III trial evaluated the efficacy and safety of capivasertib in combination with fulvestrant versus fulvestrant alone in patients with advanced HR+ breast cancer.  \n\n**Methods:** In this multicenter, double-blind, randomized controlled trial, 450 patients with metastatic or locally advanced HR+/HER2- breast cancer who progressed on prior endocrine therapy were enrolled. Participants were randomized 1:1 to receive either capivasertib (400 mg twice daily, 4 days on/3 days off) plus fulvestrant (500 mg intramuscularly every 28 days) or fulvestrant alone. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Statistical analysis was performed using Cox proportional hazards models with a significance threshold of *p* < 0.05.  \n\n**Results:** The capivasertib-fulvestrant group exhibited significantly worse PFS compared to the fulvestrant-alone group (median PFS: 5.2 vs. 7.8 months; HR 1.45, 95% CI 1.18\u20131.79, *p* = 0.003). OS was also inferior in the capivasertib arm (median OS: 18.4 vs. 24.1 months; HR 1.32, 95% CI 1.05\u20131.66, *p* = 0.02). ORR was lower with capivasertib (12.4% vs. 21.7%, *p* = 0.01). Grade \u22653 adverse events were more frequent in the capivasertib group (68% vs. 42%), including hyperglycemia (22%), rash (18%), and diarrhea (15%).  \n\n**Discussion:** Contrary to preclinical expectations, capivasertib significantly worsened clinical outcomes in advanced HR+ breast cancer, with reduced PFS, OS, and higher toxicity. These findings suggest that AKT inhibition may have unforeseen detrimental effects in this patient population. Further investigation into the underlying mechanisms is warranted, and caution should be exercised in the clinical use of capivasertib.  \n\n**Keywords:** Capivasertib, AKT inhibitor, hormone receptor-positive breast cancer, adverse outcomes, phase III trial.  \n\n(Word count: 280)\n\nAvailable PMIDs for Citation: 928267, 175012, 804414, 305381, 248330\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Capivasertib. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Capivasertib. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Capivasertib will worsen Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Capivasertib might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Capivasertib) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Capivasertib will worsen Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Capivasertib **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Capivasertib **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Capivasertib is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Capivasertib may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Capivasertib **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/928267/",
                    "https://pubmed.ncbi.nlm.nih.gov/175012/",
                    "https://pubmed.ncbi.nlm.nih.gov/804414/",
                    "https://pubmed.ncbi.nlm.nih.gov/305381/",
                    "https://pubmed.ncbi.nlm.nih.gov/248330/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]